company background image
DNMR

Danimer Scientific NYSE:DNMR Stock Report

Last Price

US$2.95

Market Cap

US$298.5m

7D

-5.1%

1Y

-82.4%

Updated

30 Sep, 2022

Data

Company Financials +
DNMR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

DNMR Stock Overview

Danimer Scientific, Inc., a performance polymer company, develops, produces, and provides bioplastic replacements for traditional petroleum-based plastics.

Danimer Scientific Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Danimer Scientific
Historical stock prices
Current Share PriceUS$2.95
52 Week HighUS$20.40
52 Week LowUS$2.84
Beta1.07
1 Month Change-33.71%
3 Month Change-37.50%
1 Year Change-82.37%
3 Year Changen/a
5 Year Changen/a
Change since IPO-69.43%

Recent News & Updates

Sep 30

Danimer Scientific: Biodegradable Plastics Are Still Important

Summary Danimer's vision to build biodegradable plastics has continued even as its commons have collapsed to new lows. Whilst partnerships with consumer packaged goods companies have helped the company realize healthy revenue, the recent revenue trajectory has been negative. The company is burning through cash at a high pace, and its overall liquidity position looks increasingly difficult. Danimer Scientific (DNMR) is pioneering the creation of sustainable and more natural ways to make plastic products. The Bainbridge, Georgia-based company produces biopolymers that have helped create plastic products that are biodegradable and compostable. This mission drove a significant level of investor enthusiasm when the company was listed on the NYSE via a blank check firm back in the winter of 2020. The next few months after this would come to be characterized by excessive animal spirits and unfettered expectations on the seemingly large total addressable market being pursued by Danimer. Indeed, the company had guided for revenue to reach $193 million in the current fiscal 2022, rising further to reach $513 million in fiscal 2025 with a 5-year compound annual growth rate of around 59% from fiscal 2020. Growth was meant to be bountiful and would be driven by the greater permeability of ESG in corporate America. This would drive firms to pay more attention to the great call of sustainability being demanded by their customers and would see many corporate sustainability commitments dealing with packaging enacted. Numerous sustainability-minded consumer packaged goods companies have looked at packaging improvements as a key way to meet these internal goals. Danimer has signed numerous partnerships with a broad range of companies including Nestle (NSRGY) and Bacardi on the back of this. Most recently, this will see the company partner with Mars Wrigley for two years to create biodegradable candy wrappers. Mars Wrigley, like many of its CPG peers, is looking to make 100% of its packaging reusable, recyclable or compostable by 2025. Hence, against a positive macro context, the retracement of Danimer's common shares has become an incredibly tragic outcome. It mirrors the fate of many growth stocks that went public on the hype of the now-dead SPAC boom. Their futures have seemingly been dashed by the total collapse of the stock market over the last year as a hawkish Fed raises rates to historic highs to try to fight of a multi-layered and relentless bout of inflation. The ensuing drawdown of liquidity has wreaked havoc on capital market-funded growth plans and has meant that Danimer, in just a few years after going public, has slid into relative obscurity and declined to levels that would seem alien to its initial investors back in the winter of 2020. Revenue Growth Goes Negative Even Against Demand For Biodegradable Plastics The company last reported earnings for its fiscal 2022 second quarter, which saw revenue come in at $12.7 million. This was a decrease of 12.2% from the year-ago quarter and a $2.66 million miss on consensus estimates. The company attributed the decline to lower PLA sales and lower R&D revenue. This was partially offset by an increase in Nodax PHA sales. Nodax is Danimer's biodegradable and sustainable plastic that is made through a natural fermentation process using plant oils, including soy and canola as feedstock. PHA-based resin sales were up 84.5% to $7.7 million, representing 61% of total revenues compared to 29% in the year-ago quarter. Gross profit was negative at $2.2 million versus a profit of $2 million in the comparable year-ago period, with the decline in higher margin R&D revenues contributing to this inversion. The quarter was not great. Cash burn from operations came in at $19.8 million as net loss reached $30.4 million. With capital expenditure of $50 million during the quarter, Danimer's cash and equivalents positions fell to $140 million from $210 million in the first quarter of fiscal 2022. As the company expects to spend a further $66 million to $76 million this year, its cash position stands to fall to a record public low against what remains anemic revenue growth and negative gross profits. Post-period end, Danimer embarked on a $100 million mixed securities offering to expand out a runway that looked set to end by the first half of fiscal 2023. Whilst it will significantly dilute current shareholders as it amounts to just over one-third of Danimer's current $293 million market cap, it is a necessary act by management to keep Danimer as a going concern. Biodegradable Plastics Are Still Important With only around 10% of plastics being recycled, Danimer's management still thinks they are chasing a large TAM. However, bears have argued that biodegradable plastics which aim to solve the single-use plastic dilemma are not the right solution and represent a more expensive over-engineering of the problem.

Aug 26

Danimer Scientific stock slides on $100M securities offering

Danimer Scientific (NYSE:DNMR) shares have plunged around 12% on Friday after the performance polymer company registered for a $100M mixed securities offering. Late Thursday, the company filed to sell common stock, preferred stock, debt securities, guarantees of debt securities or warrants up to an aggregate amount of $100M. The filing does not necessarily indicate that a sale has begun, or will occur in the future. Terms of the offering, including price, is yet to be determined.

Aug 17
These Analysts Think Danimer Scientific, Inc.'s (NYSE:DNMR) Sales Are Under Threat

These Analysts Think Danimer Scientific, Inc.'s (NYSE:DNMR) Sales Are Under Threat

The analysts covering Danimer Scientific, Inc. ( NYSE:DNMR ) delivered a dose of negativity to shareholders today, by...

Shareholder Returns

DNMRUS ChemicalsUS Market
7D-5.1%-1.2%-2.5%
1Y-82.4%-15.4%-23.2%

Return vs Industry: DNMR underperformed the US Chemicals industry which returned -13.5% over the past year.

Return vs Market: DNMR underperformed the US Market which returned -21.5% over the past year.

Price Volatility

Is DNMR's price volatile compared to industry and market?
DNMR volatility
DNMR Average Weekly Movement13.7%
Chemicals Industry Average Movement6.4%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: DNMR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: DNMR's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2004282Stephen Croskreyhttps://www.danimerscientific.com

Danimer Scientific, Inc., a performance polymer company, develops, produces, and provides bioplastic replacements for traditional petroleum-based plastics. It produces polyhydroxyalkanoate, a biodegradable plastic feedstock alternative used in a range of plastic applications, including films, straws, food containers, and other things under the Nodax brand name; polylactic acid-based resins for coating disposable paper cups; and other biopolymers. The company offers its products for biopolymers, including additives, aqueous coatings, fibers, filaments, films, thermoforming, and injection-molded articles.

Danimer Scientific Fundamentals Summary

How do Danimer Scientific's earnings and revenue compare to its market cap?
DNMR fundamental statistics
Market CapUS$298.47m
Earnings (TTM)-US$61.45m
Revenue (TTM)US$58.54m

5.1x

P/S Ratio

-4.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DNMR income statement (TTM)
RevenueUS$58.54m
Cost of RevenueUS$62.12m
Gross Profit-US$3.58m
Other ExpensesUS$57.87m
Earnings-US$61.45m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.61
Gross Margin-6.11%
Net Profit Margin-104.97%
Debt/Equity Ratio56.0%

How did DNMR perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is DNMR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DNMR?

Other financial metrics that can be useful for relative valuation.

DNMR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue7.7x
Enterprise Value/EBITDA-4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does DNMR's PS Ratio compare to its peers?

DNMR PS Ratio vs Peers
The above table shows the PS ratio for DNMR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average0.9x
FF FutureFuel
0.7xn/aUS$264.3m
ASPN Aspen Aerogels
2.6x37.7%US$372.9m
RYAM Rayonier Advanced Materials
0.1x0.2%US$201.5m
VHI Valhi
0.3xn/aUS$711.5m
DNMR Danimer Scientific
5.1x53.5%US$298.5m

Price-To-Sales vs Peers: DNMR is expensive based on its Price-To-Sales Ratio (5.1x) compared to the peer average (0.9x).


Price to Earnings Ratio vs Industry

How does DNMR's PE Ratio compare vs other companies in the US Chemicals Industry?

Price-To-Sales vs Industry: DNMR is expensive based on its Price-To-Sales Ratio (5.1x) compared to the US Chemicals industry average (1x)


Price to Sales Ratio vs Fair Ratio

What is DNMR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DNMR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.1x
Fair PS Ratio2.8x

Price-To-Sales vs Fair Ratio: DNMR is expensive based on its Price-To-Sales Ratio (5.1x) compared to the estimated Fair Price-To-Sales Ratio (2.8x).


Share Price vs Fair Value

What is the Fair Price of DNMR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate DNMR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DNMR's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Danimer Scientific forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


29.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DNMR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DNMR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DNMR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DNMR's revenue (53.5% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: DNMR's revenue (53.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DNMR's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Danimer Scientific performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-47.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: DNMR is currently unprofitable.

Growing Profit Margin: DNMR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DNMR is unprofitable, and losses have increased over the past 5 years at a rate of 47.8% per year.

Accelerating Growth: Unable to compare DNMR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DNMR is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (21.1%).


Return on Equity

High ROE: DNMR has a negative Return on Equity (-13.02%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Danimer Scientific's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: DNMR's short term assets ($202.0M) exceed its short term liabilities ($30.6M).

Long Term Liabilities: DNMR's short term assets ($202.0M) do not cover its long term liabilities ($288.3M).


Debt to Equity History and Analysis

Debt Level: DNMR's net debt to equity ratio (26.3%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if DNMR's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DNMR has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: DNMR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 76.7% each year


Discover healthy companies

Dividend

What is Danimer Scientific current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Danimer Scientific Dividend Yield vs Market
How does Danimer Scientific dividend yield compare to the market?
SegmentDividend Yield
Company (Danimer Scientific)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Chemicals)2.4%
Analyst forecast in 3 Years (Danimer Scientific)n/a

Notable Dividend: Unable to evaluate DNMR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DNMR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DNMR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DNMR's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as DNMR has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Stephen Croskrey (61 yo)

6.5yrs

Tenure

US$71,863,803

Compensation

Mr. Stephen E. Croskrey has been the Chief Executive Officer and Director of Danimer Scientific, Inc. since February 2016 and serves as its Chairman of the Board since December 2020. Mr. Croskrey was Legac...


CEO Compensation Analysis

Stephen Croskrey's Compensation vs Danimer Scientific Earnings
How has Stephen Croskrey's remuneration changed compared to Danimer Scientific's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$61m

Mar 31 2022n/an/a

US$8m

Dec 31 2021US$72mUS$875k

-US$60m

Sep 30 2021n/an/a

-US$51m

Jun 30 2021n/an/a

-US$61m

Mar 31 2021n/an/a

-US$102m

Dec 31 2020US$29mUS$424k

-US$9m

Sep 30 2020n/an/a

-US$9m

Jun 30 2020n/an/a

-US$3m

Mar 31 2020n/an/a

-US$11m

Dec 31 2019US$6mUS$394k

-US$20m

Compensation vs Market: Stephen's total compensation ($USD71.86M) is above average for companies of similar size in the US market ($USD1.72M).

Compensation vs Earnings: Stephen's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: DNMR's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: DNMR's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: DNMR insiders have only sold shares in the past 3 months.


Recent Insider Transactions

NYSE:DNMR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
19 Aug 22SellUS$872,893Stuart PrattIndividual175,327US$5.25

Ownership Breakdown

What is the ownership structure of DNMR?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders13,096,84112.9%
Institutions43,034,64842.5%
General Public45,044,58044.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.5%.


Top Shareholders

Top 25 shareholders own 43.06% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.75%
BlackRock, Inc.
8,852,366$26.1m30.37%no data
5.12%
Stephen Croskrey
5,182,358$15.3m0%no data
4.49%
The Vanguard Group, Inc.
4,543,214$13.4m-24.97%no data
3.71%
Phillip Calhoun
3,754,709$11.1m0%no data
3.45%
Invesco Ltd.
3,492,655$10.3m-8.61%no data
1.94%
State Street Global Advisors, Inc.
1,961,218$5.8m5.28%no data
1.65%
Integrated Advisors Network LLC
1,673,560$4.9m0%0.35%
1.51%
Geode Capital Management, LLC
1,530,034$4.5m20.39%no data
1.4%
Stuart Pratt
1,419,238$4.2m-11%no data
1.22%
Marshall Wace LLP
1,230,609$3.6m17.35%0.01%
0.82%
Capital Investment Advisors, LLC
830,998$2.5m0.36%0.09%
0.81%
Greenlight Capital, Inc.
821,000$2.4m0%0.18%
0.8%
Northern Trust Global Investments
810,965$2.4m-3.44%no data
0.78%
BMO Asset Management Corp.
786,040$2.3m-12.92%no data
0.76%
Royal Bank of Canada, Banking & Securities Investments
764,921$2.3m-0.99%no data
0.71%
Teramo Advisors, LLC
715,000$2.1m-43.03%1.62%
0.67%
John Dowdy
673,208$2.0m0%no data
0.62%
Newtyn Management, LLC
625,000$1.8m25%0.37%
0.61%
Charles Schwab Investment Management, Inc.
614,458$1.8m-2.53%no data
0.59%
Corbin Capital Partners, L.P.
600,000$1.8m0%0.35%
0.56%
Invesco Capital Management LLC
566,917$1.7m-37.34%no data
0.54%
John Amboian
545,915$1.6m0%no data
0.53%
Bank of America Corporation, Asset Management Arm
534,721$1.6m33.63%no data
0.52%
Progeny 3, Inc.
521,757$1.5m0%0.31%
0.51%
Forum Financial Management, LP
519,260$1.5m-40.09%0.08%

Company Information

Danimer Scientific, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Danimer Scientific, Inc.
  • Ticker: DNMR
  • Exchange: NYSE
  • Founded: 2004
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Implied Market Cap: US$298.469m
  • Shares outstanding: 101.18m
  • Website: https://www.danimerscientific.com

Number of Employees


Location

  • Danimer Scientific, Inc.
  • 140 Industrial Boulevard
  • Bainbridge
  • Georgia
  • 39817
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DNMR *BMV (Bolsa Mexicana de Valores)YesNew Common StockMXMXNMay 2020
DNMRNYSE (New York Stock Exchange)YesNew Common StockUSUSDMay 2020
6CUMUN (Boerse Muenchen)YesNew Common StockDEEURMay 2020
6CUDB (Deutsche Boerse AG)YesNew Common StockDEEURMay 2020

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/30 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.